Review outlines risks of agranulocytosis in patients taking metamizole, indicating the need for awareness about symptoms.
Metamizole is a powerful analgesic drug whose varying regulatory status from country to country reflects its mixed benefit-risk profile. Patients must be instructed about the risk of agranulocytosis and the symptoms by which it can be recognized early.
No takes yet. Share an insight, caveat, or question.
Cascorbi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: